Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09MJJ
|
|||
| Drug Name |
RP4010
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | |
| Company |
Rhizen PharmaceuticalsLa Chaux-de-Fonds, Switzerland
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-release activated calcium channel (CRACM) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Platelet activation | ||||
| Primary immunodeficiency | ||||
| Pathway Interaction Database | TCR signaling in naï | |||
| TCR signaling in naï | ||||
| Reactome | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||
| WikiPathways | Signaling by the B Cell Receptor (BCR) | |||
| Platelet homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.